ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BioFuture™ 2024 Wraps Up: Hundreds of High-Profile Attendees Joined Record Numbers of Investors and Media

- Join Us in January for More Investor and Partnering Meetings and High Profile Panels at Biotech Showcase -

Demy-Colton’s BioFuture™ conference wrapped up in New York and virtually with the largest turnout in the event’s history. 100+ speakers, 100+ investors, 62 presenting companies and 48 journalists participated in dozens of public, private and seed-stage innovation company presentations, 2,085 one-to-one meeting requests, 440 meetings scheduled and media interviews focused on the future of the life sciences, diagnostics, techbio, pharmaceutical, health delivery and digital health sectors.

BioFuture’s “Big Think” Plenary Sessions, fireside chats and workshops are poised to transform healthcare over the coming decade – from policy to AI and bioelectronics to the evolving funding landscape, among others.

Speakers included:

  • Susan Hockfield, Ph.D., former president of MIT
  • Kevin Tracey, M.D., President and CEO, Feinstein Institutes for Medical Research at Northwell Health
  • Wade Davis, Vice President of Computational Science & Head of Digital for Research, Moderna
  • Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Member of the Executive Committee, Ipsen
  • Seema Kumar, CEO, Cure
  • Daniella Kranjac, Founding General Partner, Avant Bio
  • Victoria Lipinska, Americas Lead for Quantum Innovation Centers, IBM
  • Congressman Jake Auchincloss, MA-04
  • Georgia Ravitz, Partner, FDA & Healthcare Regulatory, Orrick
  • Nouhad Husseini, SVP, Head of Business Development and Corporate Strategy, Regeneron Pharmaceuticals
  • And members of the media, including Max Bayer of Endpoints News, Hilary Brueck of Business Insider, Uduak Thomas of Genetic Engineering & Biotechnology News and Sony Salzman of ABC News, among others.

“The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding investors, and eventual issues with the ability and willingness to pay for them... Panelists offered a range of viewpoints on these and other hot topics,” said Scrip reporter Alaric DeArment in coverage following the event.

HelloPartnering is still open and will remain accessible for 6 months (April 30th). Attendees will be able to contact each other but not schedule meetings. Registered participants can access BioFuture’s on-demand access to company presentations and session recordings by logging into HelloPartnering with their registration details.

“Innovation thrives when visionary leaders and innovators come together,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “The conference’s growth this year is a testament to the value it delivers to participants in understanding the market, policy and other factors that impact the future of their businesses and healthcare. This year’s dialog tackled some of the most complex challenges in medicine and healthcare delivery – from the emergence of techbio to the implementation of the Inflation Reduction Act. Our industry is at an important inflection point, and we look forward to continuing these future leading conversations at Biotech Showcase in January.”

Biotech Showcase is the premier investor conference for private and micro to mid-cap biotechnology companies. It brings together 3,400 attendees – including nearly 1,300 investors and 110 members of the media.

For more information, please visit www.biofuture.com or follow us on X at @DemyColton and #BioFuture2024. For information about Biotech Showcase or to apply to present or sponsor, please visit www.biotech-showcase.com.

About BioFuture

Sponsored by Aisling Capital, Pappas Capital, Regeneron, JP Morgan, BioWorld, Emerald Bioventures, KKH Advisors, BKW, Cure, ENTENTE Network of Companies/ENMEDIA, EntityRisk, IPSEN, Mineralys, NYC Economic Development Corporation, Orrick, and Wilson Sonsini, BioFuture is the premier conference where therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health.

About Demy-Colton

Demy-Colton is a premier life sciences events organization committed to connecting industry leaders and fostering partnerships that advance life sciences innovation globally. Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, and the Biotech CEO Summits in Europe and La Jolla, as well as virtual events designed to keep life sciences professionals connected year-round.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.